TigerConnect Appoints Sean O’Neal as CEO, Marking a Bold New Chapter of Innovation and Growth Strategic leadership transition signals TigerConnect’s continued commitment to transform healthcare collaboration through an expanded, unified communications platform...
TigerConnect Strengthens Global Presence with New Mexico City Office Strategic regional expansion aims to attract local talent and enhance delivery of the company’s unified healthcare communications solutions TigerConnect, the leading unified healthcare communications...
Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer – Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median...
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial – VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in...
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants...
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock BOULDER, Colo., April 2, 2025 /PRNewswire/ — Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing...
Recent Comments